动脉灌注联合膀胱灌注在膀胱癌术后应用的临床研究  

Clinical Study of interventional chemotherapy and intravesical instillation for preventing recurrence of su-perficial bladder cancer

作　　者：薛耀勤[1] 温树伟[1] 畅俊平[1] 

机构地区：[1]山西省肿瘤医院介入治疗科,太原030013

出　　处：《中国医疗前沿》2013年第21期61-61,77,共2页China Healthcare Innovation

基　　金：山西省肿瘤医院院基金资助项目

摘　　要：目的研究动脉灌注联合膀胱灌注吡柔比星预防浅表性膀胱癌术后复发的临床意义。方法 32例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术后随机分为两组各16例,分别采用动脉灌注加膀胱灌注吡柔比星和吡柔比星单纯膀胱灌注治疗。结果平均随访23个月。动脉灌注联合膀胱灌注组肿瘤复发1例,单纯吡柔比星灌注组肿瘤复发5例,两组肿瘤复发率差异显著(P<0.05)。结论动脉灌注联合膀胱灌注比柔吡星预防浅表性膀胱癌术后复发疗效较好,副反应少,临床应用安全可靠。Objective To study the therapeutic efficacy of combined interventional chemotherapy and in-travesical instillation of pirarubicin on preventing bladder cancers from recurring after local ablation. Methods 32 patients with superficial bladder cancers were randomized into combined interventional chemotherapy and intrav-esical instillation of pirarubicin or intravesical instillation of pirarubicin alone for preventing recurrence after local ab-lation. Results The patients have been followed up for 12-28 months. 1 case has had tumor recurrence in the combined modality therapy group and 5 in the intravesical instillation alone group,the tumor recurrence rate being 6%（1/16） and 31%（5/16） respectively（P 〈0.05）. Conclusions Combined use of interventional chemotherapy and intravesical instillation of pirarubicin is effective in preventing superficial bladder cancer from recurring after local ablation with fewer adverse effects. The ragimen is not only reliable but also safe.

关 键 词：膀胱肿瘤 癌 灌注法 动脉 

分 类 号：R737.14[医药卫生—肿瘤]